Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.33 |
| ▸ | FDPS | P14324 | 4/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27520359 | 0.79 | LMNA (0.38) | NR1I2OPRM1LMNADNM1FDPS | |
| SCHEMBL1133423 | 0.79 | LMNA (0.38) | NR1I2OPRM1LMNADNM1FDPS | |
| SCHEMBL4441750 | 0.79 | LMNA (0.52) | LMNATSHRSPHK1 | |
| SCHEMBL27522609 | 0.77 | LMNA (0.37) | NR1I2OPRM1LMNADNM1FDPS | |
| SCHEMBL22623564 | 0.73 | NR1I2 (0.38) | NR1I2OPRM1LMNADNM1FDPS | |
| SCHEMBL1018909 | 0.71 | GPR84 (0.45) | LMNAFDPSGPR84SPHK1FFAR1 | |
| SCHEMBL8524531 | 0.68 | NR1I2 (0.45) | NR1I2TSHR | |
| SCHEMBL6685367 | 0.67 | NR1I2 (0.56) | NR1I2OPRM1LMNA | |
| SCHEMBL9631580 | 0.67 | LMNA (0.35) | NR1I2OPRM1LMNADNM1TSHR | |
| SCHEMBL252431 | 0.62 | ALDH1A1 (0.57) | OPRM1LMNADNM1FDPSTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188063-B2 | A2A receptor agonists for the central nervous system; antiinflammatory agents; 2,7-disubstituted-5-amino-pyrazolo[4,3-e]-[1,2,4]-triazolo[1,5-c]pyrimidines, mefloquine, 8-(3-chlorostyryl)caffeine, 3,7,8-trisubstituted-1-propargyl-xanthines; 2,5-disubstituted-7-amino-[1,2,4]triazolo[1,5-a][1,3,5]triazines | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-29 | — | — | US | claimed |
| US-8178509-B2 | Method to treat sickle cell disease | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-15 | — | — | US | claimed |
| US-20080064653-A1 | USE OF ADENOSINE A2A MODULATORS TO TREAT SPINAL CORD INJURY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2008-03-13 | — | — | US | claimed |
| US-20080027022-A1 | METHOD TO TREAT GASTRIC LESIONS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2008-01-31 | — | — | US | claimed |
| US-20080009460-A1 | METHOD TO TREAT SICKLE CELL DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-01-10 | — | — | US | claimed |
| WO-2007120972-A2 | METHOD TO TREAT SICKLE CELL DISEASE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-10-25 | — | — | WO | claimed |
| WO-2007092936-A9 | METHOD TO TREAT GASTRIC LESIONS | UNIV VIRGINIA (US) | 2007-10-18 | — | — | WO | claimed |
| WO-2007092936-A2 | METHOD TO TREAT GASTRIC LESIONS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-08-16 | — | — | WO | claimed |
| US-20140213541-A1 | AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATING RECURRENT TUMOR GROWTH | ADENOSINE THERAPEUTICS, LLC (US) | 2014-07-31 | — | — | US | disclosed |
| US-8551972-B2 | Agonists of A2A adenosine receptors for treating recurrent tumor growth | ADENOSINE THERAPEUTICS, LLC (US) | 2013-10-08 | — | — | US | disclosed |
| US-20130123208-A1 | METHOD OF TREATING MULTIPLE SCLEROSIS WITH ADENOSINE RECEPTOR AGONISTS | The Regents of the University of Colorado, a body corporation (US) | 2013-05-16 | — | — | US | disclosed |
| US-8188063-B2 | A2A receptor agonists for the central nervous system; antiinflammatory agents; 2,7-disubstituted-5-amino-pyrazolo[4,3-e]-[1,2,4]-triazolo[1,5-c]pyrimidines, mefloquine, 8-(3-chlorostyryl)caffeine, 3,7,8-trisubstituted-1-propargyl-xanthines; 2,5-disubstituted-7-amino-[1,2,4]triazolo[1,5-a][1,3,5]triazines | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-29 | — | — | US | disclosed |
| US-8178509-B2 | Method to treat sickle cell disease | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
| WO-2011143442-A1 | A METHOD OF TREATING MULTIPLE SCLEROSIS WITH ADENOSINE RECEPTOR AGONISTS | TROVIS PHARMACEUTICALS, LLC. (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20080064653-A1 | USE OF ADENOSINE A2A MODULATORS TO TREAT SPINAL CORD INJURY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2008-03-13 | — | — | US | disclosed |
| US-20080027022-A1 | METHOD TO TREAT GASTRIC LESIONS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2008-01-31 | — | — | US | disclosed |
| US-20080009460-A1 | METHOD TO TREAT SICKLE CELL DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-01-10 | — | — | US | disclosed |
| WO-2007120972-A2 | METHOD TO TREAT SICKLE CELL DISEASE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007092936-A9 | METHOD TO TREAT GASTRIC LESIONS | UNIV VIRGINIA (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007092936-A2 | METHOD TO TREAT GASTRIC LESIONS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123208-A1 | METHOD OF TREATING MULTIPLE SCLEROSIS WITH ADENOSINE RECEPTOR AGONISTS | ADORA3, ADORA2A, ADORA2B | NR1I2 2807/4885OPRM1 351/4885LMNA 2273/4885 |
| US-20080064653-A1 | USE OF ADENOSINE A2A MODULATORS TO TREAT SPINAL CORD INJURY | ADORA2A, ADORA2B, ADORA3 | NR1I2 3410/4885OPRM1 248/4885LMNA 2260/4885 |
| US-20140213541-A1 | AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATING RECURRENT TUMOR GROWTH | ADORA2A, ADORA3, ADORA1 | NR1I2 549/4885OPRM1 220/4885LMNA 4253/4885 |
| US-20080009460-A1 | METHOD TO TREAT SICKLE CELL DISEASE | PDE4A, ADORA2A, PDE4B | NR1I2 2623/4885OPRM1 994/4885LMNA 2878/4885 |
| US-20080027022-A1 | METHOD TO TREAT GASTRIC LESIONS | ADORA2A, ADORA2B, PDE4A | NR1I2 2964/4885OPRM1 1536/4885LMNA 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.